Immune Tolerance

Download PDF

Recent Publications on Immune Tolerance:
Ex vivo priming of CD4 T cells converts immunological tolerance into effective antitumor immunity in a murine model of acute lymphoblastic leukemia. Tumor escape mechanisms in leukemia are not well defined. To dissect...	18th July, 2008	1Department of Pediatric Hematology and Oncology, Hannover Medical School,	Leukemia. 2008 Jul 17;. DOI Direct Link
Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. The mammalian immune system discriminates between modes of cell death;...	18th July, 2008	Department of Ophthalmology and Visual Sciences, Washington University	Immunity. 2008 Jul;29(1):21-32. DOI Direct Link
Characterization of a lymphocyte subset displaying a unique regulatory activity in human decidua. One of the most intriguing mechanisms of early pregnancy is the maternal...	17th July, 2008	Goldyne Savad Institute of Gene Therapy, Hadassah University Hospital,	Int Immunol. 2008 Jul 14;. DOI Direct Link
Investing in hemophilia care: benefits and costs for patients and society. Despite the success of recent investments in health technology, inhibitor...	17th July, 2008	Center of Pharmacoeconomics, Department of Medical Pharmacology,	Semin Hematol. 2008 Apr;45(2 Suppl 1):S31-4. DOI Direct Link
Avidity maturation of memory CD8 T cells is limited by self-antigen expression. Immune tolerance to self-antigens is a complex process that utilizes...	16th July, 2008	Department of Immunology, University of Connecticut Health Center,	J Exp Med. 2008 Jul 14;. DOI Direct Link
→View more research publications.

BioNews Results for Immune Tolerance:
Statement: The U. S. Transplant Games	NIAID:  Jul 11 2008 9:29PM Matching: immune tolerance
Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published	Pharma Live:  Jul 2 2008 9:58AM Matching: immune tolerance
Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published	DiGiTAL50:  Jul 1 2008 5:45PM Matching: immune tolerance
Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published	Genetic Engineering News:  Jun 30 2008 2:25PM Matching: immune tolerance

Immune Tolerance Clinical Trials:
Glucose Tolerance in Acromegaly: The Influence of GH-Excess on Glucose Metabolism and Insulin Resistance	Acromegaly;   Diabetes;   Insulin Resistance;   Impaired Glucose Tolerance

Immune Tolerance Patents:
US Patent No.	Title
7267960	Antagonists and agonists of LDCAM and methods of use
7297482	Structurally biased random peptide libraries based on different scaffolds
7297763	Crystallization of IGF-1
7300651	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
7303881	Antigen delivery compositions and methods of use
→View more patents.

Companies working in the area of Immune Tolerance from Bioportfolio's Biocorporate database :
Company Name
Beta-Cell Beta-Cell is engaged in the development and commercialisation of innovative cell and drug therapies for the treatment of diabetes. The primary therapeutic focus of the company is on beta-cells, the... www.beta-cell.com/        View full profile
Cellular Technology Ltd. Cellular Technology Ltd. (CTL) Laboratories specializes in GLP compliant high-throughput ELISPOT testing of clinical samples. We offer consulting in assay design, provide reagents and protocols for... www.immunospot.com/        View full profile
Keel Pharmaceuticals, Inc. Keel Pharmaceuticals, Inc. is a private biopharmaceutical company that is developing new therapies to treat type 1 diabetes and other autoimmune diseases. Keels technology is based on the... www.keelpharmaceuticals.com/        View full profile
→View more Immune Tolerance related companies.

BioPortfolio Ltd. offers e-mail and postal lists for Immune Tolerance scientists - we have details of around 2520 individuals working on Immune Tolerance .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.